Andrew G Bostom

Summary

Affiliation: Rhode Island Hospital
Country: USA

Publications

  1. doi Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes
    Andrew G Bostom
    Rhode Island Hospital, Division of Kidney Diseases and Hypertension, 593 Eddy Street, Providence, RI 02903, USA
    J Clin Lipidol 5:281-7. 2011
  2. ncbi Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels
    Andrew G Bostom
    Division of Renal Diseases, Rhode Island Hospital, Providence, Rhode Island 02903, USA
    J Am Soc Nephrol 13:2140-4. 2002
  3. ncbi Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid-fortified cereal grain flour
    Andrew G Bostom
    Division of Renal Diseases, Rhode Island Hospital, Providence 02903, USA
    Arterioscler Thromb Vasc Biol 22:488-91. 2002
  4. doi Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial
    Andrew G Bostom
    Rhode Island Hospital, 110 Lockwood Street, Providence, RI 02903, USA
    Circulation 123:1763-70. 2011
  5. pmc Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial
    Andrew G Bostom
    Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, USA
    Am J Kidney Dis 53:121-8. 2009
  6. pmc Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial
    Darbie Maccubbin
    Rhode Island Hospital, Division of Kidney Diseases and Hypertension, 593 Eddy Street, Providence, RI, 02903, USA
    Clin J Am Soc Nephrol 5:582-9. 2010
  7. ncbi Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial
    Andrew G Bostom
    Rhode Island Hospital, Providence, RI 02903, USA
    Am Heart J 152:448.e1-7. 2006
  8. ncbi Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy
    Allon N Friedman
    Division of Nephrology, Indiana University School of Medicine, 1481 W 10th Street 111N, Indianapolis, IN 46202, USA
    J Am Soc Nephrol 16:3397-402. 2005
  9. ncbi C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy
    Allon N Friedman
    Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Kidney Int 68:773-8. 2005
  10. ncbi Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy
    Allon N Friedman
    Division of Nephrology, Indiana University School of Medicine, 1481 W 10th St 111N, Indianapolis, IN 46202, USA
    Atherosclerosis 172:121-5. 2004

Collaborators

Detail Information

Publications19

  1. doi Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes
    Andrew G Bostom
    Rhode Island Hospital, Division of Kidney Diseases and Hypertension, 593 Eddy Street, Providence, RI 02903, USA
    J Clin Lipidol 5:281-7. 2011
    ..Niacin compounds lower serum phosphorus concentrations in patients with end-stage renal disease...
  2. ncbi Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels
    Andrew G Bostom
    Division of Renal Diseases, Rhode Island Hospital, Providence, Rhode Island 02903, USA
    J Am Soc Nephrol 13:2140-4. 2002
    ..Further studies are needed to confirm the generalizability of these findings for this patient subgroup...
  3. ncbi Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid-fortified cereal grain flour
    Andrew G Bostom
    Division of Renal Diseases, Rhode Island Hospital, Providence 02903, USA
    Arterioscler Thromb Vasc Biol 22:488-91. 2002
    ..These findings have important implications for the statistical power of clinical trials testing the hypothesis that tHcy-lowering treatment may reduce recurrent atherothrombotic event rates...
  4. doi Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial
    Andrew G Bostom
    Rhode Island Hospital, 110 Lockwood Street, Providence, RI 02903, USA
    Circulation 123:1763-70. 2011
    ..Observational studies of patients with chronic kidney disease suggest increased homocysteine is a risk factor for cardiovascular disease. The impact of lowering total homocysteine levels in kidney transplant recipients is unknown...
  5. pmc Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial
    Andrew G Bostom
    Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, USA
    Am J Kidney Dis 53:121-8. 2009
    ..Few clinical trials of homocysteine lowering have been conducted in persons with CKD before reaching end-stage renal disease. Kidney transplant recipients are considered individuals with CKD...
  6. pmc Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial
    Darbie Maccubbin
    Rhode Island Hospital, Division of Kidney Diseases and Hypertension, 593 Eddy Street, Providence, RI, 02903, USA
    Clin J Am Soc Nephrol 5:582-9. 2010
    ..We examined whether niacin administration also reduces serum phosphorus concentrations in patients who have dyslipidemia and are free of advanced renal disease...
  7. ncbi Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial
    Andrew G Bostom
    Rhode Island Hospital, Providence, RI 02903, USA
    Am Heart J 152:448.e1-7. 2006
    ..The Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial is designed to evaluate whether lowering tHcy using vitamin supplementation reduces CVD events in renal transplant recipients...
  8. ncbi Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy
    Allon N Friedman
    Division of Nephrology, Indiana University School of Medicine, 1481 W 10th Street 111N, Indianapolis, IN 46202, USA
    J Am Soc Nephrol 16:3397-402. 2005
    ..Previous positive findings can potentially be explained through tHcy's role as a sensitive surrogate marker for kidney disease, itself a recognized cardiovascular risk factor...
  9. ncbi C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy
    Allon N Friedman
    Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Kidney Int 68:773-8. 2005
    ..However, CRP has not been tested in the high-cardiovascular risk population of type 2 diabetic nephropathy...
  10. ncbi Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy
    Allon N Friedman
    Division of Nephrology, Indiana University School of Medicine, 1481 W 10th St 111N, Indianapolis, IN 46202, USA
    Atherosclerosis 172:121-5. 2004
    ..Patients with diabetic nephropathy are at elevated cardiovascular risk. C-reactive protein (CRP) has been used to successfully predict cardiovascular events...
  11. ncbi The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: a randomized, controlled study
    Allon N Friedman
    Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN, USA
    Am J Kidney Dis 41:442-6. 2003
    ..We designed a randomized placebo-controlled study to determine the effect of prolonged oral NAC therapy on lowering tHcy levels in vitamin-replete chronic hemodialysis patients...
  12. ncbi Effects of polymorphisms of methionine synthase and methionine synthase reductase on total plasma homocysteine in the NHLBI Family Heart Study
    Paul F Jacques
    Jean Mayer USDA, Human Nutrition Research Center on Aging at Tufts University, 711 Wasington Street, Boston, MA 02111, USA
    Atherosclerosis 166:49-55. 2003
    ..This study provides no evidence that these common MTR and MTRR mutations are associated with alterations in plasma homocysteine...
  13. ncbi Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk
    Geoffrey H Tofler
    Royal North Shore Hospital, St Leonards, NSW 2065, Australia
    Thromb Haemost 88:799-804. 2002
    ..Since thrombosis plays an important role in plaque development and acute coronary syndromes, hyperhomocysteinemia may increase risk by increasing the thrombotic potential...
  14. ncbi Distribution of plasma folate forms in hemodialysis patients receiving high daily doses of L-folinic or folic acid
    Haifa Ghandour
    Vitamin Metabolism, Jean Mayer United States Department of Agriculture, Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts 02111, USA
    Kidney Int 62:2246-9. 2002
    ....
  15. ncbi Proteinuria as a predictor of total plasma homocysteine levels in type 2 diabetic nephropathy
    Allon N Friedman
    Vitamin Metabolism and Aging, Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts 02111, USA
    Diabetes Care 25:2037-41. 2002
    ..We tested the hypothesis that proteinuria independently predicts tHcy levels in a larger cohort of type 2 diabetic patients with nephropathy throughout a much broader range of kidney disease and proteinuria...
  16. ncbi Hyperhomocysteinemia in renal transplant recipients
    Allon N Friedman
    Vitamin Metabolism and Aging, Tufts Jean Mayer USDA HNRCA, Boston, MA, USA
    Am J Transplant 2:308-13. 2002
    ..For this reason, RTRs have been chosen as an ideal study population in investigating the effect of reducing hyperhomocysteinemia on CVD outcomes...
  17. ncbi B vitamins and restenosis after coronary angioplasty
    Andrew G Bostom
    N Engl J Med 346:1093-5. 2002
  18. ncbi Cost-effectiveness of homocysteine-lowering therapy to prevent coronary heart disease
    Andrew G Bostom
    JAMA 287:190; author reply 191-2. 2002
  19. ncbi Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis
    Allon N Friedman
    Vitamin Metabolism and Aging, Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts 02111, USA
    J Am Soc Nephrol 13:265-8. 2002
    ..Clinical trials will be necessary to confirm that NHD is effective in reducing tHcy levels among patients with dialysis-dependent end-stage renal disease...

Research Grants6

  1. Serum Total Homocysteine and C-Reactive Protein as Pred
    Andrew Bostom; Fiscal Year: 2002
    ....
  2. Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial
    Andrew Bostom; Fiscal Year: 2007
    ..An ongoing NIH-funded FAVORIT ancillary study (R01 DK65114-03 "FAVORIT Ancillary Cognitive Trial [FACT]" is already providing unprecedented data on cognitive function and affect in chronic renal transplantation. ..
  3. A Randomized, Controlled Trial for Homocysteine
    Andrew Bostom; Fiscal Year: 2007
    ..An ongoing NIH-funded FAVORIT ancillary study (RO1 DK65114-03 "FAVORIT Ancillary Cognitive Trial [FACT]" is already providing unprecedented data on cognitive function and affect in chronic renal transplantation. ..